Pasar al contenido principal

Hacia una mejora en las estrategias de diagnóstico y tratamiento y una mejor comprensión del impacto de los factores extrínsecos para el control de la tuberculosis. ADVANCE-TB

PI22/01834

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis, data from the prospective INNOVA4TB cohort study in Ukraine

  • Dudnyk, Andrii|||0000-0002-8780-9480
  • Hempel, M.
  • Lytvyniuk, O.
  • Liudkevych, H.
  • Matsera, V.
  • Nikitchenko, T.
  • Blyzniuk, S.
  • Molina-Moya, Barbara|||0000-0001-5144-2165
  • Preyer, R.
  • Domínguez, José|||0000-0001-7888-0309
Background: Ukraine remains a high World Health Organization priority country for drug-resistant tuberculosis (TB). Rifampicin-resistant TB (RR-TB) has a more protracted, more complicated, and more expensive treatment. In 2021, Ukraine reported 4025 RR-TB cases - 5.4 times more (751) than all 30 European Union/ European Economic Area countries together. Objectives: The objective of the study was to determine the diagnostic accuracy of line probe assay (LPA), AID Autoimmun Diagnostika GmbH, for detecting resistance to anti-TB drugs and its clinical application for selecting treatment regimens. Design: A prospective observational cohort study. Methods: From May 2019 to June 2020, we consecutively enrolled patients with active TB hospitalized at the Regional Phthisiopulmonology Center (Vinnytsia, Ukraine), aged between 18 and 82 years. The LPA was performed in the Genetic Research Laboratory at National Pirogov Memorial Medical University, Vinnytsia, Ukraine. Results: A total of 84 clinical specimens and 97 culture isolates from 126 TB patients were tested during the study. Accuracy (95% confidence interval) of LPA for clinical samples in comparison with phenotypic drug susceptibility test (DST) was 80.1 (68.5-89.0) for isoniazid (H), 74.7 (62.4-84.6) for rifampicin (R), 74.4 (62.5-84.1) for ethambutol, 71.4 (41.9-91.6) for streptomycin, 84.6 (62.4-96.5) for prothionamide/ethionamide, and 84.6 (73.6-92.3) for levofloxacin (Lfx), respectively. We found a significantly higher sensitivity of LPA for H, R, and Lfx for the culture isolates compared to clinical specimens (p < 0.05). LPA detected different mutations in 6 out of 17 (35.5%) patients susceptible to R by Xpert. A shorter treatment regimen with an injectable agent demonstrated a low suitability rate of 5% (8/156) in a cohort of RR-TB patients from Ukraine. Conclusion: Initial LPA testing accurately identifies resistance to anti-TB drugs and facilitates the selection of an appropriate treatment regimen, minimizing exposure to empirical therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Benchtop NMR urine metabolomics for diagnosing pulmonary tuberculosis

  • Comella-del-Barrio, Patricia|||0000-0002-2433-9864
  • Rodríguez, Ignacio
  • Bimba, John|||0000-0001-7847-4271
  • Osazuwa, Okoedoh
  • Alaran, Ramota
  • Alonso, Pilar
  • Blasco Iturri, Zuriñe
  • Miguel-Coello, Ana B
  • Cuevas, Luis E.|||0000-0002-6581-0587
  • Ruiz-Cabello, Jesús|||0000-0001-8681-5056
  • Izquierdo-Garcia, José Luis
  • Domínguez, José|||0000-0001-7888-0309
Tuberculosis (TB) remains a major global health issue, especially in resource-limited settings, where rapid and accurate diagnosis is critical yet often lacking. Nuclear magnetic resonance (NMR)-based metabolomics has emerged as a promising tool for identifying disease-specific biomarkers. This study assessed the diagnostic potential of urinary metabolomics using high-resolution (HR-)NMR and benchtop NMR (bNMR) in Nigerian adults with presumed pulmonary TB, including individuals with and without HIV. Urine samples were analysed by HR-NMR and bNMR. Multivariate analysis was used to develop classification models based on confirmed TB status. Key discriminant metabolites were identified. In HIV-negative individuals, HR-NMR achieved 84% sensitivity and 86% specificity, while bNMR reached 83% and 84%, respectively. In people living with HIV, HR-NMR reached 75% sensitivity and 70% specificity; bNMR achieved 90% and 46%. Both models met or exceeded WHO sensitivity criteria for non-sputum-based TB diagnostics. Thirteen discriminatory metabolites were identified, with eight consistent with previous studies. These findings suggest common metabolic signatures of TB, regardless of HIV status. Urinary NMR-based metabolomics shows strong potential for TB diagnosis in high TB/HIV burden settings. HR-NMR provides excellent accuracy, while bNMR offers a cost-effective alternative. Further studies are needed to validate and optimise this approach for clinical use.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

The study of immunological markers in tuberculosis across animal models and its translation to human research

  • Díaz-Fernández, Sergio
  • Aleluia, Matilde
  • Saraiva, Margarida
  • Soldevilla, Pablo
  • Torrelles, Jordi B.
  • Sharan, Riti
  • Verreck, Frank A. W.
  • Izzo, Angelo
  • Vidal, Maria
  • Moreira, Ana C.
  • Pérez de Val, Bernat
  • Roca, Francisco Jose
  • Preda, Madalina
  • Torrents, Eduard
  • Julián, Esther
  • Domínguez, José
  • Latorre, Irene
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, remains one of the major causes of death from infection worldwide, with over a million associated deaths each year. The study of biomarkers for TB is critical for advancing our understanding and management of the disease. Biomarkers, defined as measurable indicators of biological states or conditions, are invaluable for the diagnosis, prognosis and treatment monitoring of TB. Clinical studies have provided critical knowledge on the matter but are also notoriously constrained by economical, ethical and sampling limitations. The use of animal models provides a simpler, more controllable, cost-effective setting with great potential for translation to humans. They also allow the evaluation of biomarkers within the respiratory compartment, when available, which is of particular interest due to the nature of TB pathogenesis. This Review focuses on the current landscape of TB biomarker discovery in several animal models, from invertebrates to large mammals. Here we summarize the basics of host–pathogen immune interaction, describe the main methodological approaches used and highlight the most substantial findings for each animal model studied. Furthermore, we discuss the advantages, challenges and limitations associated with species-specific differences in animal models. We conclude that integrating the data obtained from animal models and human studies is absolutely required to advance the TB field to accelerate the management of this disease., This article is based upon work from COST Action ‘Towards an improvement in diagnostics and treatment strategies for TB control’ (ADVANCE-TB), CA21164, supported by COST (European Cooperation in Science and Technology). This work has been also supported by grants from the Instituto de Salud Carlos III (PI21/00724, PI22/01834 and CP20/00070 to I.L.) integrated in the Plan Nacional I+D+I and co-founded by the ISCIII Subdireccion General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and CERCA Programme/Generalitat de Catalunya. F.J.R. is the recipient of ‘la Caixa’ Foundation grant LCF/PR/HR21-00368, MCIN and ‘ESF Investing in your Future’ grants RYC2019-027799-I/AEI/10.13039/501100011033 and PID2022-139754OB-100, and a Robles Chillida Foundation Grant. The Institute of Agrifood Research and Technology (IRTA) is supported by CERCA Programme/Generalitat de Catalunya. J.B.T. was partially supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation. R.S. is recipient of National Institutes of Health (NIH) awards K01OD031898, R21AI170148 and R56AI184089-01A1, and other institutional grants P30 AI-161943 (Texas D-CFAR). J.B.T. and R.S. are part of IN-TRAC P30AI168439. E.J. and E.T. are recipients of grants from the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (AEI), Spain, cofunded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (PID2021-122331OB-I00 and PID2021-125801OB-100) and AGAUR-Generalitat de Catalunya (2021SGR-0092 and 2021SGR-0145). E.J. is a Serra Hunter Fellow., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The study of immunological markers in tuberculosis across animal models and its translation to human research

  • Díaz-Fernández, Sergio
  • Aleluia, Matilde
  • Saraiva, Margarida
  • Soldevilla, Pablo
  • Torrelles, Jordi B.
  • Sharan, Riti
  • Verreck, Frank A. W.
  • Izzo, Angelo
  • Vidal, Maria
  • Moreira, Ana C.
  • Pérez de Val, Bernat
  • Roca, Francisco Jose
  • Preda, Madalina
  • Torrents, Eduard
  • Julián, Esther
  • Domínguez, José
  • Latorre, Irene
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, remains one of the major causes of death from infection worldwide, with over a million associated deaths each year. The study of biomarkers for TB is critical for advancing our understanding and management of the disease. Biomarkers, defined as measurable indicators of biological states or conditions, are invaluable for the diagnosis, prognosis and treatment monitoring of TB. Clinical studies have provided critical knowledge on the matter but are also notoriously constrained by economical, ethical and sampling limitations. The use of animal models provides a simpler, more controllable, cost-effective setting with great potential for translation to humans. They also allow the evaluation of biomarkers within the respiratory compartment, when available, which is of particular interest due to the nature of TB pathogenesis. This Review focuses on the current landscape of TB biomarker discovery in several animal models, from invertebrates to large mammals. Here we summarize the basics of host–pathogen immune interaction, describe the main methodological approaches used and highlight the most substantial findings for each animal model studied. Furthermore, we discuss the advantages, challenges and limitations associated with species-specific differences in animal models. We conclude that integrating the data obtained from animal models and human studies is absolutely required to advance the TB field to accelerate the management of this disease., This article is based upon work from COST Action ‘Towards an improvement in diagnostics and treatment strategies for TB control’ (ADVANCE-TB), CA21164, supported by COST (European Cooperation in Science and Technology). This work has been also supported by grants from the Instituto de Salud Carlos III (PI21/00724, PI22/01834 and CP20/00070 to I.L.) integrated in the Plan Nacional I+D+I and co-founded by the ISCIII Subdireccion General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and CERCA Programme/Generalitat de Catalunya. F.J.R. is the recipient of ‘la Caixa’ Foundation grant LCF/PR/HR21-00368, MCIN and ‘ESF Investing in your Future’ grants RYC2019-027799-I/AEI/10.13039/501100011033 and PID2022-139754OB-100, and a Robles Chillida Foundation Grant. The Institute of Agrifood Research and Technology (IRTA) is supported by CERCA Programme/Generalitat de Catalunya. J.B.T. was partially supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation. R.S. is recipient of National Institutes of Health (NIH) awards K01OD031898, R21AI170148 and R56AI184089-01A1, and other institutional grants P30 AI-161943 (Texas D-CFAR). J.B.T. and R.S. are part of IN-TRAC P30AI168439. E.J. and E.T. are recipients of grants from the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (AEI), Spain, cofunded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (PID2021-122331OB-I00 and PID2021-125801OB-100) and AGAUR-Generalitat de Catalunya (2021SGR-0092 and 2021SGR-0145). E.J. is a Serra Hunter Fellow., info:eu-repo/semantics/publishedVersion